NCT06609850 The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma
| NCT ID | NCT06609850 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sun Yat-sen University |
| Condition | Recurrent Hepatocellular Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 116 participants |
| Start Date | 2024-10-01 |
| Primary Completion | 2026-10-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 116 participants in total. It began in 2024-10-01 with a primary completion date of 2026-10-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Studies have shown that combination therapy of TACE with Lenvatinib could achieve better survival outcomes than TACE alone for hepatocellular carcinoma (HCC) at BCLC B stage. However, whether patients could benefit from the ablation for intermediate recurrent HCC (RHCC) is still need high quality clinical evidence. This study is to evaluate the efficacy of ablation combined with TACE and Lenvatinib for the intermediate-stage RHCC.
Eligibility Criteria
Inclusion Criteria: 1. 18-75 years; 2. RHCC diagnosed by imaging; 3. intermediate-stage RHCC (two to three lesions which at least one was \>3 cm in size or more than three tumors); 4. the tumor number was no more than six, and the maximum tumor diameter was ≤5 cm; 5. absence of extrahepatic metastasis or macrovascular invasion; 6. Child-Pugh class A or B; 7. TACE as initial treatment after tumor recurrence and showed no tumor progression after TACE. 8. life expectance \>3 months; Exclusion Criteria: 1. under 18 years or over 75 years of age; 2. primary intermediate-stage HCC; 3. RHCC with more than six tumors, or single RHCC (5) RHCC \>5cm; (6) extrahepatic metastasis; (7) macrovascular tumor thrombus;
Contact & Investigator
Feng Duan
STUDY DIRECTOR
Chinese PLA General Hospital
Frequently Asked Questions
Who can join the NCT06609850 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Recurrent Hepatocellular Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06609850 currently recruiting?
Yes, NCT06609850 is actively recruiting participants. Contact the research team at zhouqun988509@163.com for enrollment information.
Where is the NCT06609850 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06609850 clinical trial?
NCT06609850 is sponsored by Sun Yat-sen University. The principal investigator is Feng Duan at Chinese PLA General Hospital. The trial plans to enroll 116 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.